N itric oxide (NO) is synthesized from L-arginine by NO synthases (NOSs). Three distinct isozymes of NOS have been identified to date: 2 Ca 2ϩ /calmodulin-dependent constitutive isozymes dominantly expressed in the brain and endothelium, and a Ca 2ϩ -independent, cytokine-inducible isozyme (iNOS). 1 iNOS produces large amounts of NO in response to bacterial lipopolysaccharides (LPS) and certain cytokines in a variety of cells, including vascular smooth muscle cells (VSMCs). 2 NO possesses diverse physiological properties, such as vasodilation, neurotransmission, and mediation of immune responses. 1 High-output NO produced by iNOS in VSMCs not only causes inhibition of cell proliferation but apoptosis of VSMCs as well. 3, 4 Therefore, regulation of iNOS gene expression has been implicated in the pathogenesis of vascular remodeling and atherosclerosis. 5 Many of the biological effects of NO have been attributed to cGMP generation via the stimulation of soluble guanylate cyclase, although a cGMP-independent mechanism is also involved in its diverse actions.
The promoter region of the rat and mouse iNOS gene contains several potential cis-elements for the binding of different transcription factors, among which 2 putative binding sites for nuclear factor-kappa B (NF-B) exist in the upstream (GGGGATTTTCC, nucleotides Ϫ965 to Ϫ955: NF-Bu) and downstream (GGGGACTCTCC, nucleotides Ϫ107 to Ϫ97: NF-Bd) regions. [6] [7] [8] The sequence of NF-Bd is unique in that it is found only in murine and human iNOS genes. It has been shown that a key region of the promoter activity in mediation of LPS inducibility resides in the NF-Bd region in mouse macrophages. 6, 7 However, its role in mediation of iNOS expression in response to cytokines in VSMCs remains largely unknown.
NF-B complexes function as a pleiotropic regulator of many genes modulating immunologic and inflammatory pro-cesses. NF-B contains heterodimeric complexes, usually consisting of p50 and p65 (Rel-A) subunits and p50/p50 homodimers in human VSMCs. 9 p50/p65 heterodimer associates with its cytoplasmic inhibitor, IB-␣, to form an inactive cytoplasmic ternary complex. p65 subunit may also complex with p105, a precursor protein of p50, as an inactive form. Activation of NF-B by LPS or cytokines requires either degradation of IB-␣ 10 or proteolytic cleavage of p105 through a common ubiquitin-proteasome pathway after phosphorylation. 11 After degradation of IB-␣, an active NF-B translocates to the nucleus and activates the expression of a plethora of genes. Recently, a cytokine-responsive IB-␣ kinase (IKK) that activates NF-B by phosphorylation of Ser 32 and Ser 36 residue in IB-␣ has been identified. [12] [13] [14] [15] [16] It has been reported that NO inhibits NF-B by induction and stabilization of IB-␣ in human endothelial cells. 17 However, it remains unknown whether NO inhibits cytokine-induced NF-B activation via inhibition of phosphorylation and degradation of IB-␣, thereby blocking iNOS gene expression in VSMCs.
These observations led us to examine (1) whether interleukin (IL)-1␤-induced iNOS gene expression is mediated by the NF-B activation pathway involving phosphorylation and subsequent degradation of IB-␣ in cultured rat VSMCs and (2) whether NO inhibits IL-1␤-induced iNOS gene expression by interfering with phosphorylation and subsequent degradation of IB-␣.
Methods

Materials
Human recombinant IL-1␤ was kindly provided by Otsuka Pharmaceutical. Murine recombinant tumor necrosis factor (TNF)-␣ was purchased from Gibco BRL; (Ϯ)-(E)-ethyl-2-[(E)-hydroxyamino]-5-nitro-3-hexeneamide (NOR3), SDS, and EDTA were purchased from Wako Pure Chemical; 8-bromo-cGMP, N-acetyl-L-cysteine, 1H-oxadiazolo-1,2,4-[4,3,-␣]quinoxaline-1-one (ODQ), PMSF, DTT, poly(dI-dC), and EGTA were purchased from Sigma Chemical; pyrrolidinedithiocarbamate was purchased from Katayama Chemical; sodium nitroprusside (SNP) was purchased from Calbiochem Novabiochem; MG115 was purchased from Peptide Institute; [␣-32 P]dCTP was purchased from Amersham International; and dNTP and a Klenow fragment of DNA polymerase I were purchased from Takara Shuzo.
Cell Culture
VSMCs from the thoracic aorta of 15-week-old male Wistar rats were prepared by the explant method and cultured in Dulbecco's modified Eagle's medium containing 10% FBS at 37°C in a humidified atmosphere of 95% air and 5% CO 2 as described previously. 18 Subcultured VSMCs (15th to 20th passages) from 2 independent isolates were used in the experiments.
Electrophoretic Mobility Shift Assay (EMSA)
Confluent VSMCs (5ϫ10 6 cells per dish) pretreated with or without NO donors (NOR3, SNP) for 60 minutes were stimulated with IL-1␤ for 2 hours, washed with ice-cold PBS, and harvested in 0.4 mL ice-cold hypotonic lysis buffer (10 mmol/L HEPES, pH 7.8; 10 mmol/L KCl; 2 mmol/L MgCl 2 ; 1 mmol/L DTT; 0.1 mmol/L EDTA; 0.1 mmol/L PMSF; and 5 g/mL leupeptin). After 15 minutes of incubation, 25 L 10% Nonidet P-40 was added. The nuclei pellets were collected, resuspended in 30 L hypertonic extraction buffer (50 mmol/L HEPES, pH 7.8; 50 mmol/L KCl; 300 mmol/L NaCl; 0.1 mmol/L EDTA; 1 mmol/L DTT; 10% glycerol; and 0.1 mmol/L PMSF), and centrifuged, and the supernatant was subjected to EMSA. The single-stranded oligonucleotides (forward: 5Ј-TGGGGACTCTCC-3Ј, complement: 5Ј-AAGGGAG-AGTCC-3Ј) corresponding to the NF-B binding sequence of the downstream region (Ϫ107 to Ϫ97) of rat iNOS gene promoter 8 were annealed at 65°C for 15 minutes and filled with [␣-32 P]dCTP (111 TBq/mmol), dNTP, and a Klenow fragment of DNA polymerase I. Nuclear proteins (10 g) were incubated with 20 000 cpm 32 Plabeled NF-B double-stranded oligonucleotide and 1 g poly(dIdC) in EMSA buffer (10 mmol/L Tris-HCl, pH 7.5; 2% glycerol; 0.2 mmol/L EDTA; 0.5 mmol/L DTT; 50 mmol/L NaCl) for 30 minutes and subjected to polyacrylamide gel electrophoresis. To examine the specificity of the NF-B binding protein, the gel shift assay was performed in parallel with the same samples in the presence of a 100-fold excess unlabeled oligonucleotide as a competitor. For gel supershift assay, nuclear protein was preincubated for 30 minutes with goat polyclonal antibodies against human NF-B p50 or p65 subunit (Santa Cruz Biotechnology).
Northern Blot Analysis
Confluent VSMCs (5ϫ10 6 cells per dish) pretreated with or without NO donors (NOR3, SNP) for 60 minutes were stimulated with IL-1␤ for 6 hours, and total RNAs were extracted by the acid guanidinium thiocyanate-phenol-chloroform methods. 19 Total RNAs (20 g), separated by formaldehyde/1.1% agarose gel electrophoresis, were transferred to a Magna Graph nylon membrane (Micron Separations Inc). The cDNA probe for rat iNOS recently cloned from rat endothelial cells 20 was labeled with [␣-32 P]dCTP (111 TBq/mmol) by random-primed labeling method. RNA immobilized on the membrane was hybridized with the labeled probes, washed in 0.1ϫSSPE/ 0.5% SDS, and autoradiographed.
Western Blot Analysis
Western blot analyses were performed essentially as described. 21 Confluent cells (5ϫ10 6 cells per dish), pretreated with or without NO donors (NOR3, SNP) or MG115 for 60 minutes, were stimulated with IL-1␤ for the indicated times for IB-␣ and phospho-IB-␣, or for 15 hours for iNOS. Cells were lysed in 50 mmol/L Tris-HCl, pH 6.8 (10% glycerol, 1% SDS, 1 g/mL pepstatin, 2 g/mL leupeptin, 2 g/mL aprotinin, and 1 mmol/L PMSF). Whole-cell lysates were boiled, and extracted proteins were separated on 12% (for IB-␣ and phospho-IB-␣) or 7.5% (for iNOS) SDS-polyacrylamide gel and transferred to Hybond ECL nitrocellulose membranes (Amersham), which were incubated overnight with rabbit polyclonal antibody for human IB-␣ (1:500; Santa Cruz Biotechnology), rabbit polyclonal antibody for human phospho-IB-␣ (Ser 32 ) (1:1000; New England Biolabs), or mouse monoclonal antibody for murine iNOS (1:1000; Transduction Laboratories) at 4°C. Anti-phospho-IB-␣ antibody detects IB-␣ only when phosphorylated at Ser 32 and has no cross-reactivities with the corresponding phosphorylated Ser of IB-␤ or IB-⑀. After extensive washing, the secondary antibody (donkey anti-rabbit IgG or sheep anti-mouse IgG horseradish peroxidase; 1:500, Amersham) was applied for 1 hour, and exposure was performed by using an ECL kit (Amersham).
Immunocytochemical Staining
Subconfluent cells grown on LAB-TEK Chamber Slide (Nalge Nunc Int) were treated with IL-1␤ in the absence or presence of NOR3 for 2 hours, fixed with 70% acetone for 20 minutes at room temperature, and then washed with PBS for 10 minutes. Goat polyclonal antibody specific for NF-B p50 subunit (Santa Cruz Biotechnology) was used; the antibody did not show any cross-reactivities with p105, p52, or p100. Immunostaining was visualized with the indirect immunoperoxidase avidin-biotin-peroxidase kit (Vector Laboratory).
Results
NF-B Activation by IL-1␤
To determine whether NF-B activation was induced with IL-1␤ in rat VSMCs, EMSA was performed using synthetic oligonucleotides corresponding to the NF-Bd site (Ϫ107 to Ϫ97) of the rat iNOS promoter as a probe (Figure 1 ). IL-1␤ (10 ng/mL) caused a distinct shifted band, whereas there was no distinct band in the control cells. The specificity of the NF-B binding gel shift assay was examined using coincubation with excess unlabeled probe as a competitor. The band was completely eliminated in the presence of a 100-fold molar excess of unlabeled oligomers ( Figure 1A ). For characterization of NF-B subunits, specific antibodies for human p50 and p65 subunits were examined. The IL-1␤-induced NF-B protein-DNA complexes were supershifted by anti-p50 antibody, whereas anti-p65 antibody caused a supershifted band in addition to the reduced shifted band ( Figure 1B ).
NO Inhibits IL-1␤-Induced NF-B Activation and iNOS mRNA and Protein Expression
We studied whether NO donors affect NF-B activation and iNOS expression induced by IL-1␤ in rat VSMCs (Figure 2 ).
Northern blot analysis using rat iNOS cDNA as a probe revealed that IL-1␤ (10 ng/mL) induced iNOS mRNA expression (4.5 kb), the effects of which were dose-dependently (10 Ϫ5 to 10 Ϫ3 mol/L) suppressed by NOR3 (Figure 2A ; top panel). EMSA showed that NOR3 similarly blocked the IL-1␤-induced NF-B activation in a dose-dependent manner (10 Ϫ5 to 10 Ϫ3 mol/L) ( Figure 2A ; bottom panel). NOR3 (10 Ϫ3 mol/L) completely blocked both NF-B activation and iNOS mRNA expression stimulated by IL-1␤. SNP (10 Ϫ3 mol/L) also attenuated the IL-1␤-induced iNOS mRNA expression and NF-B activation ( Figure 2B ).
To determine whether the inhibitory effect of NO donors is mediated via a cGMP-dependent mechanism, the effects of a selective inhibitor of soluble guanylate cyclase (ODQ) and a cell-permeable cGMP analogue (8-bromo-cGMP) were tested ( Figure 3 ). ODQ (10 Ϫ5 mol/L) did not affect the inhibitory effect of NOR3 (10 Ϫ4 mol/L) on IL-1␤-induced iNOS mRNA expression or NF-B activation ( Figure 3A ). 8-Bromo-cGMP (10 Ϫ3 mol/L) did not inhibit the IL-1␤-induced iNOS mRNA expression or NF-B activation ( Figure 3B ). Western blot analysis using specific anti-murine iNOS antibody demonstrated a distinct band of 130-kDa iNOS protein after stimulation with IL-1␤ (10 ng/mL), which was completely abolished in the presence of NOR3 (10 Ϫ4 mol/L) ( Figure 4 ). These data indicate that NO blocks IL-1␤-induced NF-B activation as well as iNOS mRNA and protein expression via a cGMP-independent mechanism.
NO Prevents IL-1␤-Induced NF-B Nuclear Translocation
To confirm that NO donor prevents nuclear translocation of active NF-B in rat VSMCs after cytokine stimulation, immunohistochemical staining using anti-p50 antibody was performed. Nonstimulated cells revealed a diffuse but faint distribution of immunoreactive p50 within the cytoplasm ( Figure 5A ). In contrast, exposure of rat VSMCs to IL-1␤ (10 ng/mL) resulted in dense accumulations of immunoreactive p50 within the nucleus (Figure 5B ), the effect of which was prevented by pretreatment with NOR3 (10 Ϫ3 mol/L) ( Figure  5D ); NOR3 added alone was without effect ( Figure 5C ).
NO Prevents IL-1␤-Induced IB-␣ Degradation
To determine whether IL-1␤ causes IB-␣ degradation in rat VSMCs, Western blot analysis using anti-IB-␣ antibody was performed. Addition of IL-1␤ (10 ng/mL) resulted in a rapid (within 15 to 30 minutes) decrease in IB-␣ protein, which then returned to baseline levels within 1 to 2 hours ( Figure 6A 
NO, but Not Proteasome Inhibitor, Prevents IL-1␤-Induced IB-␣ Phosphorylation
To determine whether IL-1␤ causes IB-␣ phosphorylation in rat VSMCs, Western blot analysis using anti-phosphoSer 32 of IB-␣ antibody was performed. Addition of IL-1␤ (10 ng/mL) resulted in a rapid (within 3 to 5 minutes) appearance of phosphorylated IB-␣, which peaked at 5 minutes and then decreased by 30 minutes ( Figure 7A ; top panel). Pretreatment with MG115 (10 Ϫ5 mol/L) stabilized the Figure 7B) ; NOR3 or MG115 added alone was without effect. These data suggest that NO inhibits rapid phosphorylation of Ser 32 of IB-␣ induced by IL-1␤ before its degradation.
Discussion
The present study clearly demonstrates that IL-1␤-induced iNOS mRNA and protein expression is associated with NF-B activation in rat VSMCs. By EMSA using a synthetic oligomer corresponding to the unique downstream NF-B site of rat iNOS promoter as a probe, we have shown that the IL-1␤ specifically activated NF-B composed of p50/p65 heterodimer that is immunologically similar, if not identical, to its human counterpart. These results are in agreement with a recent report demonstrating that NF-B complexes were mainly composed of p50/p65 heterodimers in human cultured VSMCs. 9 Transcriptional activity of p50/p65 heterodimer of NF-B can be regulated by at least 2 pathways. 11 The p50/p65 heterodimer constitutes an inactive cytoplasmic ternary complex with the inhibitor protein, IB-␣, which masks the nuclear localization sequences of p50/p65 heterodimer. IB-␣ can be rapidly phosphorylated and degraded after stimulation with LPS or cytokines, allowing transcriptionally active p50/p65 heterodimers to translocate to the nucleus to activate a set of genes related to inflammation and proliferation. An alternative pathway to regulate p65 (Rel-A) is derived from its association with the unprocessed p105, the C-terminal portion of which bears a striking resemblance to IB-␣ to form an inactive p105/p65 cytoplasmic complex. Processing of p105 results in a rapid degradation of the IB-␣ homologous sequence and formation of transcriptionally active p50/p65 heterodimer. In both pathways, phosphorylation of IB-␣ and p105 by a protein kinase(s) is essential for the subsequent degradation of IB-␣ and the processing of p105, respectively. Resynthesis of IB-␣ after its rapid degradation depends on the induction of IB-␣ expression after NF-B activation. 22 Cellular responses to cytokine signaling, such as activation of several protein kinases, including ceramide-activated protein kinase, p42/p44 mitogen-activated protein kinase, p38 mitogen-activated protein kinase, and Jun N-terminal kinase, have been suggested to exert their diverse biological consequences. 23 However, little information is yet available as to how immediate signals by cytokines cause NF-B activation in VSMCs. The present experiments using cultured rat VSMCs clearly demonstrated that stimulation with IL-1␤ caused a rapid phosphorylation of Ser 32 of IB-␣ and subsequent transient degradation of IB-␣, followed by NF-B activation and its nuclear translocation. A cytokineresponsive IB-␣ kinase recently identified phosphorylates two serine residues (Ser 32 and Ser 36 ) of IB-␣. 24 Phosphorylation of these residues is a prerequisite for polyubiquitination and subsequent degradation of IB-␣ by 20S proteasome. 25 TNF-␣ rapidly activates IB-␣ kinase, peaking at 5 to 10 minutes in HeLa cells. 24 In the present study, IL-1␤ induced a rapid (3 to 5 minutes) phosphorylation of Ser 32 residue of IB-␣, followed by a transient (15 minutes) degradation and subsequent resynthesis of IB-␣ in rat VSMCs. In the present study, a proteasome inhibitor, MG115, completely prevented the IL-1␤-induced transient degradation of IB-␣ and also stabilized the phosphorylated IB-␣ induced by IL-1␤ in rat VSMCs. These data suggest that IL-1␤ rapidly stimulates IB-␣ kinase to phosphorylate Ser 32 and possibly Ser 36 residues of IB-␣, which in turn is degraded via the ubiquitin/ proteasome pathway, thereby leading to NF-B activation in rat VSMCs. In fact, we have shown that the IL-1␤-induced NF-B activation and its nuclear translocation in rat VSMCs were completely prevented by pretreatment with MG115 (K.K. et al, unpublished data, 1998). Our present study has clearly shown that NO donors (NOR3, SNP) inhibited the IL-1␤-induced NF-B activation and its nuclear translocation, accompanied by inhibition of both iNOS mRNA and protein expression. The present study has further shown that NO donor blocked both the transient decrease in IB-␣ levels as well as its rapid phosphorylation induced by IL-1␤, whereas NO donor added alone had no effect on basal IB-␣ levels. Furthermore, NO donor abolished the appearance of IL-1␤-induced phosphorylated IB-␣, even in the presence of a proteasome inhibitor, which stabilized IB-␣. These results suggest that the inhibitory effect of NO on the IL-1␤-induced iNOS expression is mediated via inhibition of NF-B activation primarily due to its inhibition of IB-␣ phosphorylation rather than the proteasome-mediated IB-␣ degradation. Our data are in agreement with those of previous reports showing the inhibitory effects of NO on TNF-␣-induced NF-B activation in endothelial and neuronal cells. 26, 27 However, our results appear to be in contrast to 2 recent (though contradictory) reports from the same laboratory. 17, 28 Liao and his associates have shown that NO donors inhibited TNF-␣-induced NF-B activation by induction and stabilization of IB-␣ in human endothelial cells; S-nitrosoglutathione (GSNO) prevented IB-␣ degradation 30 minutes after stimulation with TNF-␣. 17 The same group has subsequently reported that GSNO did not prevent phosphorylation and degradation of IB-␣ 15 minutes after stimulation with TNF-␣ in the same cells, suggesting that NO inhibits NF-B activation by the late (2 hours) induction and nuclear translocation of IB-␣. 28 In the present study, however, NOR3 itself had no effect on basal IB-␣ expression during a 75-minute incubation period. The exact reasons for the apparent discrepancy between their reports and ours are unknown. This may be accounted for by the different cell types, species, cytokines, and NO donors used in the experiments. Among these, caution must be paid to the physicochemical nature of NO donors used, because they release NO with different kinetics and generate various metabolites that may affect cell functions. NOR3, (Ϯ)-(E)-ethyl-2-[(E)-hydroxyamino]-5-nitro-3-hexeneamide (FK409), is a novel and potent NO donor that spontaneously releases NO under neutral aqueous conditions with a half-life of 46 minutes. 29 Although the possible involvement of the metabolite cannot be excluded, concentration-dependent inhibition of NF-B activation by NOR3, with its greater potency compared with other NO donors (such as SNP and GSNO) as demonstrated in this study, strongly suggests that the effect of NOR3 is due to the biologically active NO molecule.
The exact intracellular signaling mechanism by which NO blocks cytokine-induced NF-B activation remains unknown. To address the question of whether the effect of NO is mediated by guanylate cyclase activation and subsequent cGMP generation, a cell-permeable cGMP analogue (8-bromo-cGMP) and a soluble guanylate cyclase inhibitor (ODQ) were tested. 8-Bromo-cGMP did not inhibit IL-1␤-induced NF-B activation or iNOS mRNA expression, whereas ODQ did not affect the NO-induced inhibition of either NF-B activation or iNOS mRNA expression. These results argue against an intermediate role of cGMP and the involvement of cGMP-dependent protein kinase in the mechanism of NO inhibition of both NF-B activation and iNOS expression.
NO modifies activities of several heme-and nonhemecontaining enzymes by direct nitrosylation. For example, NO interacts with the heme moiety of soluble guanylate cyclase to stimulate its enzyme activity, whereas NO inhibits enzyme activity of heme-containing iNOS. 30 NO also binds to nonheme-containing enzymes, particularly to iron-sulfur clusters (cis-aconitase, mitochondrial complexes I and II, ribonucleotide reductase), to inhibit their enzymatic activities. [31] [32] [33] NO can also modify proteins by nitrosylation of Cys residue to form S-nitrosothiols. 34 Therefore, it is possible to speculate that the inhibitory effect of NO on cytokine-induced NF-B activation may be due to its direct nitrosylation of Cys residue(s) of IB-␣ kinase to decrease its enzymatic activity. It is also possible that NO may inhibit NF-B by dephosphorylation of IB-␣, because NO has been shown to activate protein phosphatases in monocytes. 35 In fact, okadaic acid, an inhibitor of protein phosphatase 2A, has been shown to activate NF-B and induce IB-␣ phosphorylation. 36 NO may function as an antioxidant to scavenge pro-oxidants, such as superoxide anion and hydrogen peroxide, which in turn stimulate redox-sensitive protein kinase(s) to activate NF-B. 37 However, antioxidants, such as N-acetyl-L-cysteine and pyrrolidinedithiocarbamate, failed to block IL-1␤-induced NF-B activation and IB-␣ degradation in our cell culture (K.K. et al, unpublished data, 1998).
The NO-induced suppression of cytokine-induced IB-␣ phosphorylation and degradation in rat VSMCs as demonstrated in the present study, along with the direct inhibition by NO on the enzyme activity of iNOS as recently reported, 30 may constitute an auto-inhibitory mechanism to lessen the magnitude of NO-induced deleterious effects by high-output iNOS. Excessive NO production by augmented iNOS expression in the blood vessel, such as in inflammation, atherosclerosis, and septic shock, could be terminated not only via inhibition of iNOS enzyme activity, but also via transcriptional inhibition of iNOS gene by NO per se. Because NO inhibits cytokine-induced endothelial expression of adhesion molecules (vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1) and proinflammatory cytokines (IL-1␤, IL-8) via inhibition of NF-B, 38 the ability of NO to inhibit NF-B to decrease iNOS gene expression in VSMCs may also contribute to the prevention of atherogenesis and inflammation in the vessel walls.
